Sparano JA - Search Results

1

Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events.

Ip EH, Saldana S, Miller KD, Carlos RC, Gareen IF, Sparano JA, Graham N, Zhao F, Lee JW, O'Connell NS, Cella D, Peipert JD, Gray RJ, Wagner LI. Ip EH, et al. Among authors: sparano ja. Cancer. 2021 Dec 15;127(24):4546-4556. doi: 10.1002/cncr.33992. Epub 2021 Nov 2. Cancer. 2021. PMID: 34726788 Free PMC article.

2

Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha.

Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, Shechner R, Boley SJ, Gucalp R, Ciobanu N, et al. Sparano JA, et al. Cancer. 1991 Oct 1;68(7):1538-44. doi: 10.1002/1097-0142(19911001)68:7<1538::aid-cncr2820680714>3.0.co;2-2. Cancer. 1991. PMID: 1893354

3

Increasing recognition of corticosteroid-induced tumor lysis syndrome in non-Hodgkin's lymphoma.

Sparano J, Ramirez M, Wiernik PH. Sparano J, et al. Cancer. 1990 Mar 1;65(5):1072-3. doi: 10.1002/1097-0142(19900301)65:5<1072::aid-cncr2820650504>3.0.co;2-a. Cancer. 1990. PMID: 2302658

4

Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer.

Wadler S, Tenteromano L, Cazenave L, Sparano JA, Greenwald ES, Rozenblit A, Kaleya R, Wiernik PH. Wadler S, et al. Among authors: sparano ja. Cancer Chemother Pharmacol. 1994;34(3):266-9. doi: 10.1007/BF00685088. Cancer Chemother Pharmacol. 1994. PMID: 8004762 Clinical Trial.

5

Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.

Sparano JA, Wadler S, Liebes L, Robert NJ, Schwartz EL, Dutcher JP. Sparano JA, et al. Cancer Res. 1993 Aug 1;53(15):3509-12. Cancer Res. 1993. PMID: 8339255 Clinical Trial.

6

Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-hodgkin lymphoma.

Desai J, Mitnick RJ, Henry DH, Llena J, Sparano JA. Desai J, et al. Among authors: sparano ja. Cancer. 1999 Nov 1;86(9):1840-7. Cancer. 1999. PMID: 10547559

7

Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes.

Salman HS, Tanaka K, Sparano JA. Salman HS, et al. Among authors: sparano ja. Clin Breast Cancer. 2002 Jan;2(4):299-303. doi: 10.3816/cbc.2002.n.006. Clin Breast Cancer. 2002. PMID: 11899362 Clinical Trial.

8

Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.

Sparano JA. Sparano JA. Clin Breast Cancer. 2000 Apr;1(1):32-40; discussion 41-2. doi: 10.3816/CBC.2000.n.002. Clin Breast Cancer. 2000. PMID: 11899388 Review.

9

A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer.

Miller KD, Gradishar W, Schuchter L, Sparano JA, Cobleigh M, Robert N, Rasmussen H, Sledge GW. Miller KD, et al. Among authors: sparano ja. Ann Oncol. 2002 Aug;13(8):1220-4. doi: 10.1093/annonc/mdf199. Ann Oncol. 2002. PMID: 12181245 Free article. Clinical Trial.

10

Inhibiting Ras signaling in the therapy of breast cancer.

Li T, Sparano JA. Li T, et al. Among authors: sparano ja. Clin Breast Cancer. 2003 Feb;3(6):405-16; discussion 417-20. doi: 10.3816/CBC.2003.n.005. Clin Breast Cancer. 2003. PMID: 12636885 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

374 results

Search Page

Filters